A dispersion solution contains a complex of cerium oxide nanoparticle with protein in which a hydrodynamic diameter and zeta potential of the protein are maintained. The dispersion solution is produced by mixing a solution containing the protein with a solution containing a cerium (III) ion or with a cerium (III) salt followed by adding an oxidizing agent thereto.

This invention refers to a probiotic composition consisting of the bacteria Lactobacillus rhamnosus, Lactobacillus casei and Bifidobacterium longum, preferably of the strains L. rhamnosus CECT8361, L. casei CECT9104 and B. longum CECT7347, and its use as an antioxidant. This composition is particularly useful in the treatment and/or prevention of damage, at the molecular level, caused by oxidative stress, preferably during high intensity physical exercise.

This invention refers to a probiotic composition consisting of the bacteria Lactobacillus rhamnosus, Lactobacillus casei and Bifidobacterium longum, preferably of the strains L. rhamnosus CECT8361, L. casei CECT9104 and B. longum CECT7347, and its use as an antioxidant. This composition is particularly useful in the treatment and/or prevention of damage, at the molecular level, caused by oxidative stress, preferably during high intensity physical exercise.

A phenothiazine ferroptosis inhibitor, a preparation method therefor and an application thereof. Specifically provided is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The synthesized phenothiazine compound has a good inhibitory effect on ferroptosis and has good drug safety. Moreover, the compound can be used to prepare a ferroptosis inhibitor, and can also be used to prepare a drug for treating diseases related to ferroptosis, such as neurodegenerative diseases, tumors, tissue ischemia reperfusion injury, stroke, cardiovascular diseases, renal failure, and diabetic complications.

Disclosed are a tricyclic compound as represented by general formula (I), a pharmaceutical composition containing same, and a preparation method therefor and the medical use thereof. The compound can be used for preventing and treating a variety of diseases caused by toxic aldehydes.

##STR00001##

Disclosed are a tricyclic compound as represented by general formula (I), a pharmaceutical composition containing same, and a preparation method therefor and the medical use thereof. The compound can be used for preventing and treating a variety of diseases caused by toxic aldehydes.

##STR00001##

Tetrahydrocannabinol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description

##STR00001##

An astringency reducing agent including an arabinogalactan which has a molecular weight of from 10,000 to 1,000,000 and a ratio of 1,3-bound galactose to total galactose of 12 mol % or more, as an active ingredient. A method for reducing astringency, including blending the astringency reducing agent into an oral product including an astringent substance.

The invention provides compounds having the general formula I: ##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, subscript m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I: ##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, subscript m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.